Home › Companies › AMYLYX PHARMACEUTICALS INC. › 2024-2025
At AMYLYX PHARMACEUTICALS INC.'s shareholder meeting held June 5, 2025, in the 2024-2025 proxy season, 97 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 341 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of our named executives officers. — AMYLYX PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 58% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: AMYLYX PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 5, 2025.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and AMYLYX PHARMACEUTICALS INC.’s Form 8-K, filed June 5, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 5, 2025: 5 items on AMYLYX PHARMACEUTICALS INC.’s Form 8-K, filed June 5, 2025: 2 approved · 3 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore AMYLYX PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are AMYLYX PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 5, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Karen Firestone | 37,806,869 | -- | -- | 21,348,653 | 15,356,384 | 64% | Not verified | — |
| Elect Director: Justin Klee | 57,699,437 | -- | -- | 1,456,085 | 15,356,384 | 98% | Not verified | — |
| Elect Director: Bernhardt Zeiher, M.D. | 37,854,600 | -- | -- | 21,300,922 | 15,356,384 | 64% | Not verified | — |
| 2. Ratification of Appointment of Independent Registered Public Accounting Firm | 72,459,698 | 34,651 | 2,017,557 | -- | 0 | 99.9% | Approved | — |
| 3. Non-Binding, Advisory Vote on the Compensation of the Company's Named Executive Officers | 33,080,252 | 24,050,998 | 2,024,272 | -- | 15,356,384 | 58% | Approved | — |
Source: AMYLYX PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 5, 2025 — read the filing on EDGAR.
Each item below shows how the 97 asset managers that disclosed a AMYLYX PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
64% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: To elect the following persons to our board of directors, each to serve as a Class I director until the 2028 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Bernhardt Zeiher, M.D.
AMYLYX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Bernhardt Zeiher, M.D.”): 37,854,600 for, 21,300,922 withheld, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 64% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 23 asset managers below reported 6,017,859 for, 4,099,387 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,085,037 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 2,494,062 | Withhold |
| Fidelity | 666,711 | 0 | 0 | 1,145,075 | Mixed |
| BlackRock | 573,807 | 0 | 0 | 0 | For |
| Charles Schwab | 375,210 | 0 | 0 | 0 | For |
| Federated Hermes | 162,717 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 146,500 | Withhold |
| American Century | 0 | 0 | 0 | 113,920 | Withhold |
| Dimensional | 0 | 0 | 0 | 104,211 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 67,597 | Withhold |
| Invesco | 43,874 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 41,704 | 0 | 0 | 0 | For |
| Northern Trust | 37,616 | 0 | 0 | 0 | For |
| T. Rowe Price | 18,000 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 13,200 | Withhold |
| Equitable | 11,340 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 7,223 | Withhold |
| ProShares | 0 | 0 | 0 | 3,462 | Withhold |
| Prudential/PGIM | 0 | 0 | 0 | 2,560 | Withhold |
| John Hancock | 0 | 0 | 0 | 1,577 | Withhold |
| Innovator ETFs Trust | 985 | 0 | 0 | 0 | For |
| State Street | 575 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 283 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: To elect the following persons to our board of directors, each to serve as a Class I director until the 2028 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Justin Klee
AMYLYX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Justin Klee”): 57,699,437 for, 1,456,085 withheld, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 23 asset managers below reported 8,865,400 for, 1,251,846 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,085,037 | 0 | 0 | 0 | For |
| Aberdeen | 2,494,062 | 0 | 0 | 0 | For |
| Fidelity | 666,711 | 0 | 0 | 1,145,075 | Mixed |
| BlackRock | 573,807 | 0 | 0 | 0 | For |
| Charles Schwab | 375,210 | 0 | 0 | 0 | For |
| Federated Hermes | 162,717 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 146,500 | 0 | 0 | 0 | For |
| American Century | 113,920 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 104,211 | Withhold |
| ALPS ETF Trust | 67,597 | 0 | 0 | 0 | For |
| Invesco | 43,874 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 41,704 | 0 | 0 | 0 | For |
| Northern Trust | 37,616 | 0 | 0 | 0 | For |
| T. Rowe Price | 18,000 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 13,200 | 0 | 0 | 0 | For |
| Equitable | 11,340 | 0 | 0 | 0 | For |
| Victory Capital | 7,223 | 0 | 0 | 0 | For |
| ProShares | 3,462 | 0 | 0 | 0 | For |
| Prudential/PGIM | 0 | 0 | 0 | 2,560 | Withhold |
| John Hancock | 1,577 | 0 | 0 | 0 | For |
| Innovator ETFs Trust | 985 | 0 | 0 | 0 | For |
| State Street | 575 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 283 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
64% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: To elect the following persons to our board of directors, each to serve as a Class I director until the 2028 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Karen Firestone
AMYLYX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Karen Firestone”): 37,806,869 for, 21,348,653 withheld, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 64% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 23 asset managers below reported 5,973,985 for, 4,143,261 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,085,037 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 2,494,062 | Withhold |
| Fidelity | 666,711 | 0 | 0 | 1,145,075 | Mixed |
| BlackRock | 573,807 | 0 | 0 | 0 | For |
| Charles Schwab | 375,210 | 0 | 0 | 0 | For |
| Federated Hermes | 162,717 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 146,500 | Withhold |
| American Century | 0 | 0 | 0 | 113,920 | Withhold |
| Dimensional | 0 | 0 | 0 | 104,211 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 67,597 | Withhold |
| Invesco | 0 | 0 | 0 | 43,874 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 41,704 | 0 | 0 | 0 | For |
| Northern Trust | 37,616 | 0 | 0 | 0 | For |
| T. Rowe Price | 18,000 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 13,200 | Withhold |
| Equitable | 11,340 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 7,223 | Withhold |
| ProShares | 0 | 0 | 0 | 3,462 | Withhold |
| Prudential/PGIM | 0 | 0 | 0 | 2,560 | Withhold |
| John Hancock | 0 | 0 | 0 | 1,577 | Withhold |
| Innovator ETFs Trust | 985 | 0 | 0 | 0 | For |
| State Street | 575 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 283 | 0 | 0 | 0 | For |
Combines 10 wordings of this item as funds reported it.
58% Approved · of votes cast
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of our named executives officers.
AMYLYX PHARMACEUTICALS INC.’s own tally for this item (“3. Non-Binding, Advisory Vote on the Compensation of the Company's Named Executive Officers”): 33,080,252 for, 24,050,998 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Non-Binding, Advisory Vote on the Compensation of the Company's Named Executive Officers The stockholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 58% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,085,037 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 2,494,062 | 0 | 0 | Against |
| Fidelity | 0 | 1,811,786 | 0 | 0 | Against |
| BlackRock | 573,807 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 375,210 | 0 | 0 | Against |
| Federated Hermes | 0 | 162,717 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 0 | 146,500 | 0 | 0 | Against |
| American Century | 0 | 113,920 | 0 | 0 | Against |
| Dimensional | 0 | 104,211 | 0 | 0 | Against |
| ALPS ETF Trust | 0 | 67,597 | 0 | 0 | Against |
| Invesco | 0 | 43,874 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 41,704 | 0 | 0 | 0 | For |
| Northern Trust | 37,616 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 18,000 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 0 | 13,200 | 0 | 0 | Against |
| Equitable | 11,340 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 7,223 | 0 | 0 | Against |
| ProShares | 0 | 3,462 | 0 | 0 | Against |
| Prudential/PGIM | 0 | 2,560 | 0 | 0 | Against |
| John Hancock | 0 | 1,577 | 0 | 0 | Against |
| Innovator ETFs Trust | 0 | 985 | 0 | 0 | Against |
| State Street | 575 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 283 | 0 | 0 | Against |
Fund voting reports, all 23 managers: 4,750,079 for, 5,367,167 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 7,920,474 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0 | 6,791,209 | 0 | 0 | Against |
| TCG Crossover Management, LLC | 5,943,812 | 0 | 0 | 0 | For |
| Nantahala Capital Management, LLC | 2,934,405 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 2,494,062 | 0 | 0 | Against |
| GREAT POINT PARTNERS LLC | 0 | 0 | 2,000,000 | 0 | Abstain |
| Citadel | 1,799,427 | 0 | 0 | 0 | For |
| Woodline Partners LP | 1,626,274 | 0 | 0 | 0 | For |
| Goldman Sachs | 596,001 | 914,789 | 0 | 0 | Mixed |
| ADAR1 Capital Management, LLC | 0 | 1,445,287 | 0 | 0 | Against |
| Fidelity | 0 | 1,156,840 | 0 | 0 | Against |
| BlackRock | 1,050,497 | 0 | 0 | 0 | For |
| Point72 | 0 | 960,119 | 0 | 0 | Against |
| PFM Health Sciences, LP | 0 | 834,135 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 781,486 | 0 | 0 | Against |
| Two Sigma | 0 | 773,376 | 0 | 0 | Against |
| MARSHALL WACE, LLP | 0 | 535,909 | 0 | 0 | Against |
| Rock Springs Capital Management LP | 0 | 481,285 | 0 | 0 | Against |
| Alyeska Investment Group, L.P. | 0 | 442,210 | 0 | 0 | Against |
| Charles Schwab | 0 | 375,889 | 0 | 0 | Against |
| ORBIMED ADVISORS LLC | 0 | 348,000 | 0 | 0 | Against |
| Renaissance | 0 | 347,730 | 0 | 0 | Against |
| State Street | 265,242 | 8,441 | 0 | 0 | For |
| Aldebaran Capital, LLC | 258,003 | 0 | 0 | 0 | For |
| DE Shaw | 0 | 241,161 | 0 | 0 | Against |
Institutional-manager reports, all 88 managers: 22,754,127 for, 20,560,984 against, 2,000,000 abstained. Showing the 25 largest; every one is in the interactive database (link above).
99.9% Approved · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.
AMYLYX PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 72,459,698 for, 34,651 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 23 asset managers below reported 10,117,246 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,085,037 | 0 | 0 | 0 | For |
| Aberdeen | 2,494,062 | 0 | 0 | 0 | For |
| Fidelity | 1,811,786 | 0 | 0 | 0 | For |
| BlackRock | 573,807 | 0 | 0 | 0 | For |
| Charles Schwab | 375,210 | 0 | 0 | 0 | For |
| Federated Hermes | 162,717 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 146,500 | 0 | 0 | 0 | For |
| American Century | 113,920 | 0 | 0 | 0 | For |
| Dimensional | 104,211 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 67,597 | 0 | 0 | 0 | For |
| Invesco | 43,874 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 41,704 | 0 | 0 | 0 | For |
| Northern Trust | 37,616 | 0 | 0 | 0 | For |
| T. Rowe Price | 18,000 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 13,200 | 0 | 0 | 0 | For |
| Equitable | 11,340 | 0 | 0 | 0 | For |
| Victory Capital | 7,223 | 0 | 0 | 0 | For |
| ProShares | 3,462 | 0 | 0 | 0 | For |
| Prudential/PGIM | 2,560 | 0 | 0 | 0 | For |
| John Hancock | 1,577 | 0 | 0 | 0 | For |
| Innovator ETFs Trust | 985 | 0 | 0 | 0 | For |
| State Street | 575 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 283 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 89,080,821 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.59% |
| 2 | Aberdeen | 2.80% |
| 3 | Fidelity | 2.03% |
| 4 | BlackRock | 0.64% |
| 5 | Charles Schwab | 0.42% |
| 6 | Federated Hermes | 0.18% |
| 7 | BRIDGEWAY FUNDS INC | 0.16% |
| 8 | American Century | 0.13% |
| 9 | Dimensional | 0.12% |
| 10 | ALPS ETF Trust | 0.08% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | PERCEPTIVE ADVISORS LLC | 8.89% |
| 2 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 7.62% |
| 3 | TCG Crossover Management, LLC | 6.67% |
| 4 | Nantahala Capital Management, LLC | 3.29% |
| 5 | Aberdeen | 2.80% |
| 6 | GREAT POINT PARTNERS LLC | 2.25% |
| 7 | Citadel | 2.02% |
| 8 | Woodline Partners LP | 1.83% |
| 9 | Goldman Sachs | 1.70% |
| 10 | ADAR1 Capital Management, LLC | 1.62% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR LLC | 18.49% | 13G |
| Perceptive Advisors LLC | 9.30% | 13G |
| TCG Crossover GP II, LLC | 7.01% | 13G |
| Commodore Capital LP | 6.34% | 13G |
| Vanguard Group | 4.62% | 13F |
| Millennium Management | 3.46% | 13F |
| Citadel Advisors | 3.17% | 13F |
| Point72 Asset Management, L.P. | 3.15% | 13G |
| Adage Capital Management, L.P. | 3.12% | 13G |
| BlackRock | 2.68% | 13F |
Percentages above are of 89,080,821 shares outstanding, as reported by AMYLYX PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AMYLYX PHARMACEUTICALS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
AMYLYX PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
proxyvotesnow.com, “AMYLYX PHARMACEUTICALS (AMLX) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/amylyx-pharmaceuticals-inc/2025 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.